A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors (RTOG 1008)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Resected High Risk Malignant Salivary Gland Tumors
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    Pathologically proven diagnosis of a malignant major salivary gland tumor or malignant minor salivary gland tumor of the head and neck of the following histologic subtypes: 1) Intermediate-grade adenocarcinoma or intermediate-grade mucoepidermoid carcinoma. 2) High-grade adenocarcinoma or high-grade mucoepidermoid carcinoma or salivary duct carcinoma. 3)High-grade acinic cell carcinoma or high-grade (>30% solid component) adenoid cystic carcinoma.

You may not be eligible for this study if the following are true:

  • 1) Patients with residual macroscopic disease after surgery; 2) Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible); 3) Prior systemic chemotherapy or radiation therapy for salivary gland malignancy; note that prior chemotherapy for a different cancer is allowable; 4) Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields;


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.